Circulating	0	11	O
endothelial	12	23	B-Cell
cells	24	29	I-Cell
in	30	32	O
malignant	33	42	O
disease	43	50	O
.	50	51	O

Cancer	53	59	B-Pathological_formation
is	60	62	O
a	63	64	O
disease	65	72	O
largely	73	80	O
dependent	81	90	O
on	91	93	O
neoangiogenesis	94	109	O
.	109	110	O

Cancer	111	117	B-Pathological_formation
neoangiogenesis	118	133	O
is	134	136	O
often	137	142	O
disordered	143	153	O
and	154	157	O
abnormal	158	166	O
,	166	167	O
with	168	172	O
evidence	173	181	O
of	182	184	O
coexisting	185	195	O
vascular	196	204	B-Tissue
endothelial	205	216	I-Tissue
dysfunction	217	228	O
.	228	229	O

A	230	231	O
novel	232	237	O
method	238	244	O
of	245	247	O
assessing	248	257	O
vascular	258	266	B-Tissue
endothelial	267	278	I-Tissue
function	279	287	O
in	288	290	O
cancer	291	297	B-Pathological_formation
is	298	300	O
via	301	304	O
the	305	308	O
quantification	309	323	O
of	324	326	O
circulating	327	338	B-Cell
endothelial	339	350	I-Cell
cells	351	356	I-Cell
(	357	358	O
CEC	358	361	B-Cell
)	361	362	O
.	362	363	O

Unusual	364	371	O
in	372	374	O
healthy	375	382	O
individuals	383	394	O
,	394	395	O
their	396	401	O
presence	402	410	O
in	411	413	O
elevated	414	422	O
numbers	423	430	O
often	431	436	O
indicates	437	446	O
substantial	447	458	O
vascular	459	467	B-Tissue
endothelial	468	479	I-Tissue
perturbation	480	492	O
.	492	493	O

Another	494	501	O
interesting	502	513	O
cell	514	518	B-Cell
type	519	523	O
is	524	526	O
the	527	530	O
endothelial	531	542	B-Cell
progenitor	543	553	I-Cell
cell	554	558	I-Cell
(	559	560	O
EPC	560	563	B-Cell
)	563	564	O
,	564	565	O
whose	566	571	O
numbers	572	579	O
increase	580	588	O
in	589	591	O
the	592	595	O
presence	596	604	O
of	605	607	O
vascular	608	616	B-Tissue
damage	617	623	O
.	623	624	O

Recent	625	631	O
research	632	640	O
suggests	641	649	O
that	650	654	O
EPCs	655	659	B-Cell
have	660	664	O
an	665	667	O
important	668	677	O
role	678	682	O
in	683	685	O
tumor	686	691	B-Pathological_formation
vasculogenesis	692	706	O
.	706	707	O

Another	708	715	O
marker	716	722	O
being	723	728	O
investigated	729	741	O
in	742	744	O
the	745	748	O
context	749	756	O
of	757	759	O
vascular	760	768	B-Tissue
dysfunction	769	780	O
and	781	784	O
coagulopathy	785	797	O
is	798	800	O
the	801	804	O
endothelial	805	816	B-Cellular_component
microparticle	817	830	I-Cellular_component
(	831	832	O
EMP	832	835	B-Cellular_component
)	835	836	O
.	836	837	O

Thus	838	842	O
,	842	843	O
CECs	844	848	B-Cell
,	848	849	O
EPCs	850	854	B-Cell
and	855	858	O
EMPs	859	863	B-Cellular_component
may	864	867	O
represent	868	877	O
potentially	878	889	O
novel	890	895	O
methods	896	903	O
for	904	907	O
evaluating	908	918	O
the	919	922	O
vascular	923	931	O
status	932	938	O
of	939	941	O
cancer	942	948	B-Pathological_formation
patients	949	957	B-Organism
.	957	958	O

This	959	963	O
review	964	970	O
will	971	975	O
summarize	976	985	O
the	986	989	O
current	990	997	O
position	998	1006	O
of	1007	1009	O
CECs	1010	1014	B-Cell
,	1014	1015	O
EPCs	1016	1020	B-Cell
and	1021	1024	O
EMPs	1025	1029	B-Cellular_component
in	1030	1032	O
cell	1033	1037	B-Cell
biology	1038	1045	O
terms	1046	1051	O
,	1051	1052	O
with	1053	1057	O
particular	1058	1068	O
emphasis	1069	1077	O
on	1078	1080	O
their	1081	1086	O
relationship	1087	1099	O
to	1100	1102	O
malignant	1103	1112	O
disease	1113	1120	O
.	1120	1121	O

